Table 1

Working core outcome measurement set

Core domainOutcome measurements
CLE-specificDermatologicGeneric
Skin-Specific Disease ActivityCLASI-A
Investigator Global Assessment of Disease ActivityCLA-IGA*
Skin-Specific Disease DamageCLASI-D
Symptoms (pruritus, pain and photosensitivity)CLEQoL (includes Skindex-29 +3)DLQI
Skindex-29+3
12-Item Pruritus Severity Scale
Itch VAS/NRS
Pain VAS/NRS
Health-related Quality of LifeCLEQoL (includes Skindex-29 +3)
LEQoL
Skindex-29+3
DLQI
SF-36
EQ-5D
Patient Global Assessment of Disease Activity
  • *May be considered as a secondary or exploratory endpoint, complementary to CLASI, pending ongoing validation.

  • CLA-IGA, Cutaneous Lupus Activity Investigator’s Global Assessment; CLASI-A, Cutaneous Lupus Erythematosus Disease Area and Severity Index-Activity; CLASI-D, Cutaneous Lupus Erythematosus Disease Area and Severity Index-Damage; CLEQoL, Cutaneous Lupus Erythematosus Quality of Life; DLQI, Dermatology Life Quality Index; LEQoL, Lupus Erythematosus Quality of Life Questionnaire; NRS, Numeric Rating Scale; SF-36, Short Form Health Survey; VAS, Visual Analogue Scale.